drugset
Drugs / Genakumab
last change Jun 2026 re-read 2 minutes ago

Genakumab

also known as GenSci048 · firsekibart

Monoclonal antibody targets IL1B via inhibition

Developed for
gout · cancer · endometriosis · pulmonary systemic sclerosis · rheumatoid arthritis-associated interstitial lung disease · systemic-onset juvenile idiopathic arthritis · uveitis
Investigated by
Changchun GeneScience Pharmaceutical Co., Ltd. · Huashan Hospital · Affiliated Hospital of Nantong University · Affiliated Hospital of North Sichuan Medical College · Changhai Hospital · Hainan General Hospital
+6 more · Linyi People's Hospital · Peking Union Medical College Hospital · Shengjing Hospital · The First Affiliated Hospital with Nanjing Medical University · The Second Affiliated Hospital of Chongqing Medical University · West China Hospital

Trials 11 · a red edge is where a trial was stopped

today NCT07547995 · Ph 2 NCT06963177 · Ph 2 NCT06189495 · Ph 2 NCT05925452 · not/applicable NCT05936268 · Ph 2 NCT05936281 · Ph 2 NCT05894148 · Ph 1 NCT05983445 · Ph 3 NCT05441046 · Ph 1 NCT05328531 · Ph 1/2 NCT04337437 · Ph 1
202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05894148 Mar → Nov 2023 interstitial lung disease Changchun GeneScience Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT05441046 Jun 2022 → Jun 2024 cancer Changchun GeneScience Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04337437 Apr 2019 → Sep 2020 juvenile idiopathic arthritis Changchun GeneScience Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05328531 May 2021 → Jun 2022 gout Changchun GeneScience Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 25 trials
Phase 2 NCT07547995 Jun 2026 → Dec 2027 expected uveitis Changchun GeneScience Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT06963177 May 2025 → May 2028 expected endometriosis Changchun GeneScience Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06189495 Dec 2023 → Mar 2026 overdue pulmonary systemic sclerosis, rheumatoid arthritis-associated interstitial lung disease Changchun GeneScience Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT05936268 Jul 2023 → Feb 2024 gout Changchun GeneScience Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 2 NCT05936281 Jul 2023 → Jan 2024 gout Changchun GeneScience Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT05983445 Jan 2023 → Apr 2024 gout Changchun GeneScience Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase not applicable1 trial
— NCT05925452 Dec 2023 → Mar 2028 expected systemic-onset juvenile idiopathic arthritis Changchun GeneScience Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Genakumab “All subjects received one dose of Genakumab injection every 4 weeks according to their group.” NCT06189495 ↗
8

NCT05936268 ↗

NCT05936281 ↗

NCT05983445 ↗

NCT05441046 ↗

NCT04337437 ↗

NCT05328531 ↗

NCT05925452 ↗

NCT05894148 ↗
Known as firsekibart “This study evaluated the efficacy and safety of firsekibart, a fully human anti-IL-1β monoclonal antibody, in children with active sJIA.” PMID 41814037 ↗ Mar 2026
Known as GenSci048 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547995 ↗
1

NCT06963177 ↗
Action Inhibit “fully human anti-IL-1β monoclonal antibody” PMID 41814037 ↗ Mar 2026
Modality Monoclonal antibody “a fully human anti-IL-1β monoclonal antibody” PMID 41814037 ↗ Mar 2026
Route Subcutaneous “single subcutaneous injection of Genakumab for Injection” NCT05328531 ↗
Target IL1B “a fully human anti-IL-1β monoclonal antibody” PMID 41814037 ↗ Mar 2026